Effect of hydrophilic polymers on pioglitazone complexation with hydroxypropyl-β-cyclodextrin

Digest Journal of Nanomaterials and Biostructures

Volumn 4, Issue 4, 2009, Pages 891-897

  Gajare, Pankaj ^a   Patil, Chandrashekhar ^a   Kalyane, Navanath ^a   Pore, Yogesh ^b  

^a BLDE University Campus   (India)

^b Government College of Pharmacy   (India)

Author keywords

Dissolution; Hydrophilic carriers; Hydroxypropyl beta cyclodextrin; Inclusion complex; Phase solubility; Pioglitazone hydrochloride

Indexed keywords

EID: 78649343068     PISSN: None     EISSN: 18423582     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. S.M. Ali, S.K. Upadhyay, J. Incl. Phenom. Macrocycl. Chem. 62, 161-165 (2008).
2. K. Arii, K. Ota, T. Suehiro et al., Diabetes Res. Clin. Pr. 69, 305-308 (2005).
3. A. Pfutzner, C.A. Schneider, T. Forst, Expert Review of Cardiovascular Therapy. 4, 445-459 (2006).
4. E. Carreon-Torres, M. Juarez-Meavepena, G. Cardoso-Saldana et al., Atherosclerosis. 181, 233-240 (2005).
5. [5] Actos Description RxList.com New York: The Internet Drug Index WebMD, Inc.; c1996-2005, Available via http://www.rxlist.com/actos-drug.htm. Accessed July 15 2008.
6. L. Szente & J. Szejtli, Adv. Drug Deliv. Rev. 36, 17-28 (1999).
7. [7] D.O. Thompson, Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. In: D.O. Thompson (ed). Critical Reviews in Therapeutic Drug carrier Systems, 1997; Begell House Inc, p. 1-104.
8. K. Uekama, F. Hirayama et al., Chem. Rev. 98, 2045-2076 (1998).
9. T. Loftsson, H. Fririksdottir et al., Int. J. Pharm. 127, 293-296 (1996).
10. M. Valero, B.I. Perez-Revuelta et al., Int. J. Pharm. 253, 97-110 (2003).
11. M. Cirri, F. Maestrelli et al., J. Pharm. Biomed. Anal. 42, 126-131 (2006).
12. L. Ribeiro, T. Loftsson et al., Chem. Pharm. Bull. 51, 914-922 (2003).
13. F.J.B. Veiga, L.S.S. Ribeiro et al., Eur. J. Pharm. Sci. 20, 253-266 (2003).
14. T. Higuchi & K.A. Connors, Adv. Anal. Chem. Instr. 4, 117-212 (1965).
15. M.T. Faucci, P. Mura, Drug Dev. Ind. Pharm. 27, 909-917 (2001).
16. T. Loftsson, & H. Fririksdottir, Int. J. Pharm. 163, 115-121 (1998).
17. B. Cappello, C. Carmignani et al., Int. J. Pharm. 213, 75-81 (2001).
18. Y. Pore, M. Shah et al., Drug Dev. Ind. Pharm. 35, 118-129 (2009).
19. J.L. Ford, Pharm. Acta. Helv. 61, 69-88 (1986).
20. J.A. Ryan, J. Pharm. Sci. 75, 805-807 (1986).
21. X. Wen, F. Tan, Z. Jing, Z. Liu, J. Pharm. Biomed. Anal. 34, 517-523 (2004).
22. J. Mielcarek, J. Incl. Phenom. Macrocycl. Chem. 30, 243-252 (1998).
23. J. Cvetkovskii, R. Bettini, L.J. Tasic, M. Stupar, I. Casini, A. Rossi, F. Giordano, J. Therm. Anal. Calorim. 68, 669-678 (2002).
24. C.M. Fernandes, M.T. Vieira & F.J.B. Veiga, Eur. J. Pharm. Sci. 15, 79-88 (2002).